952345-00-5

Basic information

• Product Name: D-Proline, 1-methyl-5-oxo-
• Synonyms: D-Proline, 1-methyl-5-oxo-;1-methyl-5-oxo-D-Proline;(R)-1-Methyl-5-oxopyrrolidine-2-carboxylic acid
• CAS NO: 952345-00-5
• Molecular Formula: C6H9NO3
• Molecular Weight: 143.14056
• Mol File: 952345-00-5.mol
• Article Data: 18

Chemical Properties

• Boiling Point: 361.7±35.0 °C(Predicted)
• Appearance: /
• Density: 1.319±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 3.53±0.20(Predicted)
• CAS DataBase Reference: D-Proline, 1-methyl-5-oxo-(CAS DataBase Reference)
• NIST Chemistry Reference: D-Proline, 1-methyl-5-oxo-(952345-00-5)
• EPA Substance Registry System: D-Proline, 1-methyl-5-oxo-(952345-00-5)

Safety Data

• Hazardous Substances Data: 952345-00-5(Hazardous Substances Data)

Usage

General Description

D-Proline, 1-methyl-5-oxo-, also known as N-Methyl-D-prolinol, is a chemical compound that is commonly used in the field of organic chemistry. It is a derivative of the amino acid proline, and is often utilized as a chiral building block for the synthesis of pharmaceuticals and other biologically active compounds. This chemical has a wide range of applications, including as a catalyst in various organic reactions, as an intermediate in the production of pharmaceuticals, and as a chiral auxiliary in asymmetric synthesis. Its unique structure and properties make it a valuable tool in synthetic chemistry, particularly in the development of new drugs and materials.

Upstream product

• 6312-54-5 N,N-dimethyl-(L)-glutamic acid 
• 42435-88-1 (S)-methyl 1-methyl-5-oxopyrrolidine-2-carboxylate 
• 6753-62-4 N-methyl-L-glutamic acid 
• 4042-36-8 D-pyrrolidone-5-carboxylic acid 
• 74-88-4 methyl iodide 
• 35418-16-7 L-t-butyl pyroglutamate 
• 190783-99-4 (S)-methyl 1-methyl-5-oxopyrrolidine-2-carboxylate 
• 7149-65-7 ethyl (S)-pyroglutamate 
• 177314-35-1 1-methyl-L-pyroglutamic acid ethyl ester 
• 98-79-3 L-Pyroglutamic acid 
• 4931-66-2 methyl (S)-pyroglutamate 
• 146963-39-5 N-(o-nitrobenzyl)-L-glutamic acid dibenzyl ester 
• 146963-40-8 N-methyl-N-(o-nitrobenzyl)-L-glutamic acid dibenzyl ester 
• 146963-43-1 (S)-2-{[1-(2-Nitro-phenyl)-meth-(E)-ylidene]-amino}-pentanedioic acid dibenzyl ester 

Downstream Products

• 1428535-80-1 thioacetic acid S-{(S)-6-[((R)-1-methyl-5-oxo-pyrrolidine-2-carbonyl)-amino]-6-phenylcarbamoyl-hexyl} ester 
• 1428535-77-6 thioacetic acid S-{(S)-6-[((R)-1-methyl-5-oxo-pyrrolidine-2-carbonyl)-amino]-6-m-tolylcarbamoyl-hexyl} ester 

Relevant articles and documents

ARYLMETHYLENE HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS

A compound of Formula (I) or a pharmaceutically acceptable salt thereof is described, wherein the substituents are as defined herein. Pharmaceutical compositions comprising the same and method of using the same are also described.

MORPHINAN DERIVATIVE

A compound represented by the following general formula (I), wherein R1 represents hydrogen, C1-10 alkyl, cycloalkylalkyl where the cycloalkyl moiety has 3 to 6 carbon atoms and the alkylene moiety has 1 to 5 carbon atoms, or the like, R2 represents a 4- to 7-membered saturated heterocycle containing one or two heteroatoms which may be the same or different and are selected from N, O, and S, and two or more carbon atoms as ring-constituting atoms, the heterocycle may be substituted with a substituent such as an oxo group, R2 binds to Y via a carbon atom as a ring-constituting atom of R2, R3, R4, and R5, which are the same or different, represent hydrogen; hydroxy; or the like, R6a and R6b, which are the same or different, represent hydrogen or the like, R7 and R8, which are the same or different, represent hydrogen or the like, R9 and R10, which are the same or different, represent hydrogen or the like, X represents O or CH2, and Y represents C(= O) or the like), a tautomer of the compound, a stereoisomer of the compound, a pharmaceutically acceptable salt thereof, or a solvate thereof is used as an anxiolytic, an antidepressant, or the like.

THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE

Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.